Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Veit Schmelmer"'
Autor:
John S. Tamaresis, Andrew R. Rezvani, Kevin A. Goncalves, Judith A. Shizuru, Shaji Kumar, Matthew J. Frank, David B. Miklos, Ying Lu, Hitomi Hosoya, Laura Johnston, Douglas Girgenti, Anne Le, Sally Arai, Robert Lowsky, Andriyana K Bankova, Wen-Kai Weng, Everett Meyer, Parveen Shiraz, Lori Muffly, Surbhi Sidana, John C. Davis, Veit Schmelmer
Publikováno v:
Transplantation and Cellular Therapy. 28:S73
Background: MGTA-145, a CXCR2 agonist, has shown promising activity for hematopoietic stem cell (HSC) mobilization with plerixafor in pre-clinical models and healthy volunteers. It has the potential to become the first GCSF free regimen for HSC mobil
Autor:
David T. Scadden, Kevin A. Goncalves, Veit Schmelmer, Haley Howell, Steven M. Devine, Jonathan Hoggatt, Jan Pinkas, Patrick C. Falahee, William J. Savage, Sharon L. Hyzy, John F. DiPersio, Katelyn J. Hammond, John C. Davis
Publikováno v:
Blood. 136:31-32
Background . The majority of hematopoietic stem cell (HSC) transplants are performed using peripheral blood mobilized with granulocyte-colony stimulating factor (G-CSF) given over 5 days. The goal of a successful transplant is to reliably mobilize op
Autor:
Lori Muffly, Andrew R. Rezvani, Hitomi Hosoya, Parveen Shiraz, Laura Johnston, Matthew J. Frank, Robert Lowsky, Haley Howell, Kevin A. Goncalves, Wen-Kai Weng, Surbhi Sidana, Veit Schmelmer, Sally Arai, Andriyana K Bankova, Everett Meyer, Shaji Kumar, John D. Davis, David B. Miklos, Judith A. Shizuru
Publikováno v:
Journal of Clinical Oncology. 39:8023-8023
8023 Background: MGTA-145 (GroβT), a CXCR2 agonist, has shown promising activity for HSC mobilization with plerixafor in pre-clinical models and healthy volunteers. Methods: This phase 2 single center study evaluates HSC mobilization with MGTA-145 +
Autor:
Veit Schmelmer, J. Neale, David T. Scadden, Michael P. Cooke, Glen D. Raffel, Dwight M. Morrow, Jonathan Hoggatt, Jacky Davis, Kevin A. Goncalves, T. Boitano, John F. DiPersio, Haley Howell, William J. Savage, Patrick C. Falahee, Steven M. Devine
Publikováno v:
Annals of the Rheumatic Diseases. 79:701-702
Background:Autologous haematopoietic stem cell (HSC) transplantation is a recommended therapeutic option for selected patients with autoimmune diseases. G-CSF mobilisation of HSCs requires 4-7 days of injections that are associated with significant s
Autor:
David T. Scadden, Jonathan Hoggatt, Sharon L. Hyzy, Veit Schmelmer, Jan Pinkas, Patrick C. Falahee, Haley Howell, Kevin A. Goncalves, John C. Davis, William J. Savage, John F. DiPersio, Steven M. Devine, Katelyn J. Hammond
Publikováno v:
Transplantation and Cellular Therapy. 27:S34
Autor:
Lukasz Biernat, Dwight M. Morrow, Veit Schmelmer, Patrick C. Falahee, Jason Neale, Kevin A. Goncalves, Glen D. Raffel, Michael P. Cooke, John F. DiPersio, John C. Davis, Steven M. Devine, Jonathan Hoggatt, Haley Howell, Anthony E. Boitano
Publikováno v:
Blood. 134:1961-1961
Background Granulocyte colony-stimulating factor (G-CSF) is the standard of care for mobilization of hematopoietic stem cells (HSCs). G-CSF requires 4-7 days of injections and often multiple aphereses to acquire sufficient CD34+ cells for transplant.